Janssen Biotech, Inc.

Centocor, Inc.

Centocor Ortho Biotech Inc.

Other

The University of North Carolina at Chapel Hill

University of Pennsylvania

Michael Naso

Bernard Scallon

Jinquan Luo

Sheng-Jiun Wu

Natalie Fursov

John Wheeler

Mark Tornetta

Karen Duffy

Ravi Malaviya

Roberta Lamb

Michael Pratta

Ann Cai

LeRoy Hall

Catherine Healy

John Lee

Bethany Swencki-Underwood

Jill Marie Mooney

G Mark Anderson

Francis Joseph Carr

Timothy David Jones

Chichi Huang

Bailin Liang

David Clemmons

Laura A Maile

Xiao-Yu R Song

Simon William Keen

T Shantha Raju

Adam Cotty

Cam Ngo

Keying Ma

Frank Naso

James M Wilson

Raymond W Sweet

William Strohl

Juan C Almagro

Robert Rauchenberger

Joost Alexander Kolkman

Ronald Swanson

Anna P Tretiakova

Galina Obmolova

Thomas J Malia

Mark Rutz

Mary Ryan

Sandra Santulli-Marotto

Qiang Wang

Timothy McCabe

Chong C Huang

Maria P Limberis

Susann Taudte

Cam Holland

Robert Friesen

Daniela Della Ducata

Chen Ni Chin

Merle Elloso

Bingyuan Wu

Chris Huang

Susan Tam

Leroy Hall

Thomas Malia

Juan Carlos Almagro

Fibronectin type III (FN3) domain antibodies, polynucleotides capable of encoding the FN3 domain antibodies or antigen-binding fragments, cells expressing FN3 domain antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled FN3 domain antibodies or antigen-binding fragments may be used to engineer FN3 domain-targeting chimeric antigen receptors (CARs). Methods of making the FN3 domain antibodies, CARs, and engineered immune cells, and methods of using the engineered immune cells are applicable to treat diseases including cancer.

Antigen binding regions against fibronectin type III domains and methods of using the same

BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.

Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof

A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.

AAV mediated influenza vaccines

The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.

ST2L antagonists and methods of use

Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.

Anti-tissue factor antibodies and compositions

The present invention provides an antibody or antigen-binding fragment thereof that binds &#x3b1;&#x3b2;integrin, as well as methods of use in the treatment of diseases and disorders.

Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)

ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

ST2L antibody antagonists

Isolated polynucleotides encodingCCL17 (CynoCCL17), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

[object Object]

The properties of an Fc-containing protein, for example, an antibody, are controlled by altering the sialylation of the oligosaccharides in the Fc region by transfecting the cell line expressing the Fc-containing protein with a vector sequence encoding a sialidase. The modified Fc-containing proteins have therapeutic utility in diseases or conditions in which it is desirable to control the affinity for one or more of the Fc&#x3b3;RI, Fc&#x3b3;RIIA, and Fc&#x3b3;RIIIA receptors, ADCC activity, macrophage or monocyte activation, serum half-life, and avidity.

Methods and vectors for generating asialylated immunoglobulins

Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

IL-17A antibodies

Growing community of inventors

Spring House, PA, United States of America

Michael Naso